Literature DB >> 15382072

Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California.

Paul K Mills1, Deborah G Riordan, Rosemary D Cress, Heather A Young.   

Abstract

Perineal talc use has been suggested as a possible risk factor for ovarian cancer based on its structural similarity to asbestos, a known human carcinogen. A population-based epidemiologic case-control study of epithelial ovarian cancer (EOC) was conducted in 22 counties of Central California that comprise the reporting area for 2 regional cancer registries. Telephone interviews were conducted with 256 cases diagnosed in the years 2000-2001 and 1,122 controls frequency-matched on age and ethnicity. The interview obtained information on demographic factors, menstrual and reproductive experience, exogenous hormone use, surgical history and family history of cancer. Questions on perineal talc use included frequency of use, duration of use and specific years when talc was used. Multivariate-adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of talc was 1.37 (CI = 1.02-1.85) compared to never users. However, no dose response association was found. Tubal ligation (TL) modified the effect of talc on EOC such that women with TL had an OR of 0.88 (CI = 0.46-1.68) associated with perineal talc use, whereas women with no TL had an OR of 1.54 (CI = 1.10-2.16). Talc use and EOC risk was highest in women with serous invasive tumors (OR = 1.77; CI = 1.12-2.81). This study provides some support for the hypothesis that perineal talc use is associated with an increased risk of EOC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382072     DOI: 10.1002/ijc.20434

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates.

Authors:  Anna H Wu; Celeste L Pearce; Chiu-Chen Tseng; Malcolm C Pike
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-14       Impact factor: 4.254

Review 2.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

3.  Douching, Talc Use, and Risk of Ovarian Cancer.

Authors:  Nicole L Gonzalez; Katie M O'Brien; Aimee A D'Aloisio; Dale P Sandler; Clarice R Weinberg
Journal:  Epidemiology       Date:  2016-11       Impact factor: 4.822

Review 4.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 5.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15

6.  Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES).

Authors:  Joellen M Schildkraut; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul Terry; Sydnee Crankshaw; Fabian Camacho; Frances Wang; Patricia G Moorman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-12       Impact factor: 4.254

Review 7.  Epidemiological and genetic factors associated with ovarian cancer.

Authors:  Monica R McLemore; Christine Miaskowski; Bradley E Aouizerat; Lee-May Chen; Marylin J Dodd
Journal:  Cancer Nurs       Date:  2009 Jul-Aug       Impact factor: 2.592

Review 8.  Perineal talc use and ovarian cancer: a critical review.

Authors:  Joshua E Muscat; Michael S Huncharek
Journal:  Eur J Cancer Prev       Date:  2008-04       Impact factor: 2.497

9.  Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.

Authors:  Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Linda Titus-Ernstoff; Bernard Rosner; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

10.  Perineal powder use and risk of ovarian cancer.

Authors:  Serena C Houghton; Katherine W Reeves; Susan E Hankinson; Lori Crawford; Dorothy Lane; Jean Wactawski-Wende; Cynthia A Thomson; Judith K Ockene; Susan R Sturgeon
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.